Everything below concerns Stenabolic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-29. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
4.A.1 The PTS Glucose-Glucoside (Glc) Family 4.A.2 The PTS Fructose-Mannitol (Fru) Family 4.A.3 The PTS Lactose-N,N'-Diacetylchitobiose-β-glucoside (Lac) Family 4.A.4 The PTS Glucitol (Gut) Family 4.A.5 The PTS Galactitol (Gat) Family 4.A.6 The PTS Mannose-Fructose-Sorbose (Man) Family 4.A.7 The PTS L-Ascorbate (L-Asc) Family
I will have myself crowned King of Bohemia in Prague, and I am convinced that a new, indissoluble bond of trust and loyalty between My throne and My Bohemian Kingdom will be strengthened by this holy rite. In contrast to his predecessor Emperor Ferdinand (who spent the rest of his life after his abdication in 1848 in Bohemia and especially in Prague), Franz Joseph was never crowned separately as king of Bohemia. In 1861, the negotiations failed because of unsolved constitutional problems. However, in 1866, a visit of the monarch to Prague following defeat at the Battle of Königgrätz was a huge success, testified by the considerable numbers of new photographs taken.
Examples of iron-containing proteins in higher organisms include hemoglobin, cytochrome (see high-valent iron), and catalase. The average adult human contains about 0.005% body weight of iron, or about four grams, of which three quarters is in hemoglobin—a level that remains constant despite only about one milligram of iron being absorbed each day, because the human body recycles its hemoglobin for the iron content. Microbial growth may be assisted by oxidation of iron(II) or by reduction of iron(III).
== Function == This gene encodes a transmembrane transporter that likely plays a role in monocarboxylic acid transport. A mutation in this gene has been associated with juvenile cataracts with microcornea and renal glucosuria. [provided by RefSeq, Mar 2010].
Sources: en.wikipedia.org
== Food safety == In 2010, the U. S. Food and Drug Administration acknowledged high-purity quercetin as generally recognized as safe for use as an ingredient in various specified food categories at levels up to 500 mg per serving.
== Pathophysiology == Myasthenia gravis is an autoimmune synaptopathy. The disorder occurs when the immune system malfunctions and generates antibodies that attack the body's tissues. The antibodies in MG attack a normal human protein, the nicotinic acetylcholine receptor, or a related protein called MuSK, a muscle-specific kinase. Other, less frequent antibodies are found against LRP4, agrin, and titin proteins. Human leukocyte antigen haplotypes are associated with increased susceptibility to myasthenia gravis and other autoimmune disorders. Relatives of people with myasthenia gravis have a higher percentage of other immune disorders. The thymus gland cells form part of the body's immune system. In those with myasthenia gravis, the thymus gland is large and abnormal. It sometimes contains clusters of immune cells that indicate lymphoid hyperplasia, and the thymus gland may give wrong instructions to immune cells.
1993/453) National Rivers Authority (Anglian Region) (Reconstitution of the North Level Internal Drainage Board) Order 1992 S.I. 1993/454) Environmentally Sensitive Areas (Breckland) Designation Order 1993 (S.I. 1993/455) Environmentally Sensitive Areas (Clun) Designation Order 1993 (S.I. 1993/456) Environmentally Sensitive Areas (North Peak) Designation Order 1993 (S.I. 1993/457) Environmentally Sensitive Areas (Suffolk River Valleys) Designation Order 1993 (S.I. 1993/458) Environmentally Sensitive Areas (Test Valley) Designation Order 1993 (S.I. 1993/459) Environmentally Sensitive Areas (Pennine Dales) Designation (Amendment) Order 1993 (S.I. 1993/460) National Assistance (Sums for Personal Requirements) Regulations 1993 (S.I. 1993/462) Education (Further Education Corporations) (Designated Staff) Order 1993 (S.I. 1993/465) Bradford, Kirklees and Leeds (City and Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/473) Warwickshire and West Midlands (County and District Boundaries) Order 1993 (S.I. 1993/474) Merchant Shipping (Light Dues) (Amendment) Regulations 1993 (S.I. 1993/475) Wireless Telegraphy (Television Licence Fees) (Amendment) Regulations 1993 (S.I. 1993/476) Residential Accommodation (Relevant Premises, Ordinary Residence and Exemptions) Regulations 1993 (S.I. 1993/477) Social Security (Claims and Payments) Amendment Regulations 1993 (S.I. 1993/478) Social Fund Maternity and Funeral Expenses (General) Amendment Regulations 1993 (S.I. 1993/479) Personal Injuries (Civilians) Amendment Scheme 1993 (S.I.
Sources: en.wikipedia.org
Southern: The southern section runs from the New River and consists of the prolongation of the Blue Ridge Mountains, which is divided into the Western Blue Ridge (or Unaka) Front and the Eastern Blue Ridge Front, the Ridge-and-Valley Appalachians, and the Cumberland Plateau. This same plateau is known as the Cumberland Plateau in southern West Virginia, eastern Kentucky, far Southwest Virginia, eastern Tennessee, and northern Alabama.
== Slavery == The Global Slavery Index 2018, ranking the prevalence of modern slavery by nation, ranked Thailand 23 of 167 (1=worst; 167=best). The index claims that Thailand has 610,000 persons working in conditions of modern slavery, equating to 8.9 persons of every thousand. Other ASEAN nations ranked were: Cambodia, 9; Myanmar, 18; Brunei, 19; Laos, 22; Philippines, 30; Malaysia, 42; Indonesia, 74; Vietnam, 77; Singapore, 97. The Global Slavery Index 2016, published by the Walk Free Foundation, ranked Thailand 20 (tied with eight other countries) of 167 nations (1=worst) for the estimated percentage of its population in "modern slavery". ASEAN is well-represented in the index: Cambodia was ranked 2; Myanmar, 9; Brunei, 14; Malaysia, 29; Philippines, 33; Laos, 37; Indonesia, 39 (tied with one other country); Singapore, 45 (tied with one other country); and Vietnam, 47.
=== International === There are regular regional and international educational medical physics activities. The oldest of these is the International College on Medical Physics at the International Centre for Theoretical Physics (ICTP), Trieste, Italy. This College has educated more than 1000 medical physicists from developing countries.
== History == The process is named after the Dutch physicist Frans Michel Penning who first reported it in 1927. Penning started to work at the Philips Natuurkundig Laboratorium at Eindhoven to continue the investigation of electric discharge on rare gases. Later, he started measurements on the liberation of electrons from metal surfaces by positive ions and metastable atoms, and especially on the effects related to ionization by metastable atoms.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.